European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B[J]. J Hepatology, 2009, 50(2): 227-242.
Chang TT, Gish RG, de Man R, et al. A comparison of entecarvir and lamivudine for HbeAg-positive chronic hepatitis B[J]. N Engl J Med, 2006, 354(10): 1001-1010.
[6]
Hou J, Yin YK, Xu D, et al. Telbivudine versus lamivudine in chinese patients with chronic hepatitis B: results at 1 year of a randomized, double-blind trial[J]. Hepatology, 2008, 47(2): 447-454.
Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAG-negative chronic hepatitis B for up to 5 years[J]. Gastroenterology, 2006, 131(6): 1743-1751.
[9]
Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B[J]. N Engl J Med, 2005, 352(26): 2673-2681.
[10]
Keeffe EB, Zeuzem S, Koff RS, et al. Report of an international workshop:roadmap for management of patients receiving oral therapy for chronic hepatitis B[J]. Clin Gastroenterol Hepatol, 2007, 5(8): 890-897.
[11]
Lampertico P, Vigano M, Manenti E, et al. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistance hepatitis B patients[J]. Gastroenterology, 2007, 133(5): 1445-1451.
[12]
Yastuji H, Suzuki F, Sezaki H, et al. Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up[J]. J Hepatol, 2008, 48(6): 923-931.
[13]
Wang LC, Chen EQ, Cao J, et al. Combination of Lamivudine and adefovir therapy in HBeAg-positive chronic hepatitis B patients with poor response to adefovir monotherapy[J]. J Viral Hepatitis, 2010, 17(3): 178-184.
[14]
Delaney WET. Progress in the treatment of chronic hepatitis B: long-term experience with adefovir dipivoxil[J]. J Antimicrob Chemother, 2007, 59(5): 827-832.
[15]
Lim SG, Marcellin P, Tassopoulos N, et al. Clinical trial: effects of adefovir dipivoxil therapy in Asian and Caucasian patients with chronic hepatitis B[J]. Aliment Pharmacol Ther, 2007, 26(10): 1419-1428.
[16]
Ganem D, Prince AM. Hepatitis B virus infection-natural history and clinical consequences[J]. N Engl J MED, 2004, 350(11):1118-1129.
[17]
Fattovich G, Bortolotti E, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors[J]. J Hepatol, 2008, 48(2): 335-352.
